AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion deal includes an initial payment of $425 million, with additional contingent consideration.
AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details
